文献速递乳腺癌

节拍卡培他滨辅助治疗早期三阴性乳腺癌:SYSUCC-001 10年更新及FOXC1探索性分析

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

FOXC1高表达亚组获益更明显。

核心结论

  • 早期三阴性乳腺癌完成标准辅助治疗后,1年节拍卡培他滨带来持久的10年无病生存获益。
  • FOXC1高表达患者接受卡培他滨较观察组显示生存优势,但需验证后方可用于患者选择。

研究设计与样本

  • 开放标签、多中心、Ⅲ期随机对照试验的事后长期分析,在中国13个中心开展。
  • 入组T1b-3 N0-3c M0三阴性乳腺癌患者,完成标准辅助治疗后1:1随机接受口服节拍卡培他滨650 mg/m2每日两次用1年或观察。

关键数值与推荐

  • FOXC1生物标志物队列338例(78%),卡培他滨组171例(51%),观察组167例(49%),采用基线肿瘤样本免疫组化检测。

临床怎么用

  • 对于完成标准辅助治疗的早期三阴性乳腺癌,可考虑1年节拍卡培他滨以改善长期无病生存。
  • FOXC1高表达可能提示卡培他滨获益人群,但当前仅为探索性发现,尚不能用于常规选择。

局限性

  • 分析为事后长期随访分析,结论需谨慎解读。
  • FOXC1为探索性生物标志物分析,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the primary report of the SYSUCC-001 trial, 1 year of metronomic capecitabine improved 5-year disease-free survival in patients with operable triple-negative breast cancer. Here, we provide updated 10-year disease-free survival and overall survival data from extended follow-up, together with an exploratory analysis of FOXC1 as a potential predictive biomarker. METHODS: This post-hoc, long-term analysis of an open-label, multicentre, phase 3 trial was conducted at 13 centres in China. Eligible women with stage T1b-3 N0-3c M0 triple-negative breast cancer who had completed standard adjuvant therapy were randomly assigned (1:1) to receive oral metronomic capecitabine 650 mg/m2 twice daily for 1 year or observation. Here, we report 10-year follow-up data, including all of the original prespecified trial endpoints: disease-free survival (primary outcome), overall survival, distant disease-free survival, and locoregional recurrence-free survival analysed in the full analysis set. Exploratory biomarker analysis of FOXC1 was undertaken using immunohistochemistry on baseline tumour samples. This trial is registered with ClinicalTrials.gov, NCT01112826, and is complete. FINDINGS: Between April 23, 2010, and Dec 31, 2016, 443 participants were enrolled and randomly assigned, of whom 434 initiated the intervention as assigned and were included in the primary analysis (221 in the capecitabine group, 213 in the observation group). As of data cutoff for this analysis (March 31, 2025), 420 (97%) participants had available follow-up data and the median duration of follow-up was 116·0 months (IQR 96·0-134·8). The updated 10-year disease-free survival was significantly higher in the capecitabine group than in the observation group (78·1% vs 66·6%; hazard ratio [HR] 0·61; 95% CI 0·43-0·88; p=0·0074). 10-year overall survival was not significantly different between the two groups (82·4% vs 73·7%; HR 0·67; 95% CI 0·45-1·01; p=0·058). The 10-year distant disease-free survival rates were 78·1% versus 66·5% (HR 0·61; 95% CI 0·43-0·88; p=0·0075) and 10-year locoregional recurrence-free survival rates were 81·6% versus 69·9% (0·60; 0·40-0·89; p=0·011). The FOXC1 biomarker cohort comprised 338 (78%) patients (171 [51%] from the capecitabine group, 167 [49%] from the observation group). In FOXC1-high patients (n=149), capecitabine conferred superior disease-free survival (HR 0·33; 95% CI 0·16-0·68; p=0·0027) and overall survival (0·25; 0·10-0·62; p=0·0028) compared with observation, whereas the FOXC1-low subgroup (n=189) showed no benefit with capecitabine versus observation. INTERPRETATION: In this exploratory, long-term analysis, extended adjuvant metronomic capecitabine provided durable disease-free survival benefit in early triple-negative breast cancer, although the findings should be interpreted with caution given the post-hoc nature of the analysis. Patients with FOXC1-high tumours showed a survival advantage with capecitabine versus observation; if this finding is validated, FOXC1-driven patient selection might be useful to optimise therapeutic responses. FUNDING: National Natural Science Foundation of China and Guangdong Esophageal Cancer Institute Science and Technology Program. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Yuan J, Bi XW, Hua X, et al. Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial. Lancet Oncol. 2025. PMID: 41308674. doi:10.1016/S1470-2045(25)00545-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。